Survival of patients with Her2 positive metastatic breast cancer after failure of adjuvant treatment with trastuzumab
H.N. Rier, M. Hooning, A. Jager, J.J.E.M. Kitzen, S. Sleijfer, M.D. Levin
Voorzitter(s): prof. dr. J.W. de Fijter, LUMC, Leiden & dr. W.G. Meijer, WestFries Gasthuis, Hoorn
Woensdag 22 april 2015
15:00 - 16:00u
in Auditorium 1
Categorieën: parallelsessie (case reports/research)
Parallel sessie: Parallelsessie 1: Case reports/research
Background:
Survival of patients with Her2 positive metastatic breast cancer has improved dramatically since the availability of trastuzumab. Because most trials contain breast cancer patients, who have never been exposed to trastuzumab in adjuvant setting (TN-group), these trials might not be representative for the current population of patients adjuvantly treated with trastuzumab (T-group). In this retrospective study we hypothesized that survival of Her2 positive metastatic breast cancer patients in the T-group is worse than in the TN-group.
Methods:
All patients with Her2 positive metastatic breast cancer receiving palliative trastuzumab were identified and divided into a group that received adjuvant trastuzumab treatment (T-group) and a trastuzumab-naïve group (TN-group). Overall survival (OS) was estimated using Kaplan Meier analysis and a Cox proportional hazards model.
Results:
109 patients were identified at our hospital between 01.01.2001 and 01.06.2014, 22 patients in the T-group and 87 in the TN-group. Death rate at the end of follow up was 74.3%. Median follow up was 18.5 months in the T-group and 31.0 months in the TN-group. Median OS was 29 months in the T-group and 33 months in the TN-group. (p=0.445)
Conclusion:
This study shows no overall survival difference in patients with adjuvant trastuzumab treatment failure in relation to trastuzumab naïve patients. In order to rule out a type II statistical error, a multicenter study is planned.
